Understanding cancer biology is crucial to the successful diagnosis and application of personalized therapies. Skin carcinogenesis is a multi-step process. The first step is the development of potentially malignant disorders (PMDs) known as leukoplakia, erytroplakia, lichen planus, probably trough mutation in the proteins regulated cell cycle (p16INK4A, p21Waf1/Cip1/Sdi1, p27 kip1, Cyclin D1) and, second in p53 (TP53), Ras, hTert, EGFR, will reverse benign phenotype of late precancer lesions

more »

... Ds) into benign cancer lesion. Third mutation probably in PI3K, PKD1 or E-cadherin, will increase malignant potential of SCCs, activating EMTransition, invasion and metastasis, e.g. aggressive phenotype. In BCC mutations of p53 are known to be late events (UV signature), whereas silencing of 14-3-3 takes place early in tumor progression, concomitant with increased activity of Snail. Early increased expression of PKD1 and down-regulation of c-myc mRNA are also events in pathogenesis of BCC. There is no data for detected mutations in PKD1 gene in both cancers, although the kinases is with high expression in BCC and lack of expression in SCC. There is no data concerning PKD1 expression in the PMDs leading to SCCs, nor to BCCs, such data were recently published concerning PKD1 expression in pancreatic oncogenesis. Curently adequate question is whether lack of PKD1 expression in SCCs, despite its PMDs origin, is a consequence of its spinous layer origin, or is a consequense of PKD1 gene mutations (downregulation). Identification of mutations as markers for early malignant transformation could be useful for early diagnosis and treatment of skin head and neck cancers.